Go Pro
NASDAQ:DXCM

DexCom Q3 2026 Earnings Report

DexCom logo
$85.36 -0.87 (-1.01%)
Closing price 04:00 PM Eastern
Extended Trading
$85.36 +0.00 (+0.01%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom EPS Results

Actual EPS
N/A
Consensus EPS
$0.67
Beat/Miss
N/A
One Year Ago EPS
N/A

DexCom Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.33 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

DexCom Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Thursday, October 29, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

DexCom Earnings Headlines

DexCom (NASDAQ:DXCM) Stock: Insider Sadie Stern Sells 2,565 Shares
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.tc pixel
See More DexCom Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DexCom? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DexCom and other key companies, straight to your email.

About DexCom

DexCom (NASDAQ:DXCM) (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting. Dexcom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin, including people seeking greater insight into how everyday activities affect glucose levels.

Founded in 1999 and headquartered in San Diego, California, DexCom serves customers in the United States and international markets. Its products are distributed through healthcare providers, pharmacies, distributors and other commercial channels, with applications spanning diabetes management, remote monitoring and connected health.

View DexCom Profile